Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Chemotherapy, Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer

This early-stage study is testing a special vaccine designed to help your immune system fight a specific type of advanced lung cancer. Researchers want to see if combining this new vaccine with standard chemotherapy and immunotherapy is safe and effective.

You may be able to join if you have advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation, and you have not received prior treatment for this stage. You also need to be well enough to carry out daily activities and have tumors that can be safely biopsied and measured.

Participants will first receive standard chemotherapy and immunotherapy treatments, followed by the KRAS-targeted vaccine along with immune-boosting medications. Doctors will closely monitor your safety, track your tumor's response, and check your blood for immune system changes.

This study is currently recruiting patients in Baltimore, Maryland, United States. It is a small, single-center trial aiming to enroll around 15 patients.